Literature DB >> 24981859

Control of disease tolerance to malaria by nitric oxide and carbon monoxide.

Viktória Jeney1, Susana Ramos1, Marie-Louise Bergman1, Ingo Bechmann2, Jasmin Tischer2, Ana Ferreira1, Virginia Oliveira-Marques1, Chris J Janse3, Sofia Rebelo1, Silvia Cardoso1, Miguel P Soares4.   

Abstract

Nitric oxide (NO) and carbon monoxide (CO) are gasotransmitters that suppress the development of severe forms of malaria associated with Plasmodium infection. Here, we addressed the mechanism underlying their protective effect against experimental cerebral malaria (ECM), a severe form of malaria that develops in Plasmodium-infected mice, which resembles, in many aspects, human cerebral malaria (CM). NO suppresses the pathogenesis of ECM via a mechanism involving (1) the transcription factor nuclear factor erythroid 2-related factor 2 (NRF-2), (2) induction of heme oxygenase-1 (HO-1), and (3) CO production via heme catabolism by HO-1. The protection afforded by NO is associated with inhibition of CD4(+) T helper (TH) and CD8(+) cytotoxic (TC) T cell activation in response to Plasmodium infection via a mechanism involving HO-1 and CO. The protective effect of NO and CO is not associated with modulation of host pathogen load, suggesting that these gasotransmitters establish a crosstalk-conferring disease tolerance to Plasmodium infection.
Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24981859     DOI: 10.1016/j.celrep.2014.05.054

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  30 in total

Review 1.  Disease tolerance and immunity in host protection against infection.

Authors:  Miguel P Soares; Luis Teixeira; Luis F Moita
Journal:  Nat Rev Immunol       Date:  2017-01-03       Impact factor: 53.106

Review 2.  The Iron age of host-microbe interactions.

Authors:  Miguel P Soares; Günter Weiss
Journal:  EMBO Rep       Date:  2015-10-16       Impact factor: 8.807

3.  The Phagocyte Oxidase Controls Tolerance to Mycobacterium tuberculosis Infection.

Authors:  Andrew J Olive; Clare M Smith; Michael C Kiritsy; Christopher M Sassetti
Journal:  J Immunol       Date:  2018-07-30       Impact factor: 5.422

4.  Whole-Blood Transcriptional Signatures Composed of Erythropoietic and NRF2-Regulated Genes Differ Between Cerebral Malaria and Severe Malarial Anemia.

Authors:  Srinivas Nallandhighal; Gregory S Park; Yen-Yi Ho; Robert O Opoka; Chandy C John; Tuan M Tran
Journal:  J Infect Dis       Date:  2019-01-01       Impact factor: 5.226

5.  Vascular endothelial growth factor (VEGF) and lovastatin suppress the inflammatory response to Plasmodium berghei infection and protect against experimental cerebral malaria.

Authors:  Miriam Canavese; Andrea Crisanti
Journal:  Pathog Glob Health       Date:  2015-09-21       Impact factor: 2.894

6.  VEGF and LPS synergistically silence inflammatory response to Plasmodium berghei infection and protect against cerebral malaria.

Authors:  Miriam Canavese; Tania Dottorini; Andrea Crisanti
Journal:  Pathog Glob Health       Date:  2015-09-21       Impact factor: 2.894

Review 7.  The emerging role of gasotransmitters in the pathogenesis of tuberculosis.

Authors:  Krishna C Chinta; Vikram Saini; Joel N Glasgow; James H Mazorodze; Md Aejazur Rahman; Darshan Reddy; Jack R Lancaster; Adrie J C Steyn
Journal:  Nitric Oxide       Date:  2016-07-04       Impact factor: 4.427

Review 8.  Metabolic Adaptations to Infections at the Organismal Level.

Authors:  Katia Troha; Janelle S Ayres
Journal:  Trends Immunol       Date:  2020-01-17       Impact factor: 16.687

Review 9.  The role of declining adaptive homeostasis in ageing.

Authors:  Laura C D Pomatto; Kelvin J A Davies
Journal:  J Physiol       Date:  2017-11-21       Impact factor: 5.182

Review 10.  Pathophysiological Mechanisms in Gaseous Therapies for Severe Malaria.

Authors:  Ana Carolina A V Kayano; João Conrado K Dos-Santos; Marcele F Bastos; Leonardo J Carvalho; Júlio Aliberti; Fabio T M Costa
Journal:  Infect Immun       Date:  2016-03-24       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.